Analyst Price Target is $14.00
▲ +91.78% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Voyager Therapeutics in the last 3 months. The average price target is $14.00, with a high forecast of $14.00 and a low forecast of $14.00. The average price target represents a 91.78% upside from the last price of $7.30.
Current Consensus is
The current consensus among 1 contributing investment analysts is to buy stock in Voyager Therapeutics. This rating has held steady since October 2022, when it changed from a Hold consensus rating.
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.